• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Addition of insulin to metformin in Type 2 Diabetes may increase risk of mortality

byAshmita BanerjeeandPriyanka Vedak
June 10, 2014
in Chronic Disease, Endocrinology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1.  The addition of insulin to metformin was associated with an increased risk of all-cause mortality and an increased grouped risk of all-cause mortality and myocardial infarction (MI) or stroke relative to the addition of sulfonylureas. 

2.  The addition of insulin versus sulfonylureas to metformin did not differ in terms of rates of associated acute myocardial infarction (MI) or stroke alone. 

Evidence Rating Level: 2 (Good)

Study Rundown: The American Diabetes Association recommends metformin for first-line treatment of diabetes for a goal of 7% HbA1c. Addition of second-line agents such as insulin or sulfonylureas is often needed to achieve this goal. Although clinical practice and research favors the use of insulin, patients prefer delaying insulin initiation. There is no consensus regarding the risk of cardiovascular events and deaths and all-cause death with insulin relative to sulfonylureas. This study evaluated this risk and found that addition of insulin to metformin increased the risk of all-cause mortality and increased the grouped risk of all-cause mortality and myocardial infarction (MI) or stroke but did not differ from sulfonylureas in rates of acute MI or stroke.

While this study provides information that could be useful in choosing second-line therapy for glycemic control, it is unlikely to change clinical practice without further corroboration. Unmeasured confounders including individual differences in treatment response can affect the results. Sample size for insulin treatment was significantly smaller than that for sulfonylureas making result interpretation challenging. The study population consisted mostly of white men, thus limiting the generalizability of the study results.

Click to read the study, published today in JAMA

Click to read an accompanying editorial in JAMA

RELATED REPORTS

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

The Scan by 2 Minute Medicine®: Endometriosis Awareness Month, OnlineMedEd Charges, Canadian Grocery Store Controversy, BetterHelp’s Privacy Concerns

The Scan by 2 Minute Medicine®: Erythritol and Heart Problems, Maternal Health Trends, the Next Big Thing in Diabetes, and Declining Levels of Sea Ice

Relevant Reading: 14-year risk of all-cause mortality according to hypoglycaemic drug exposure in a general population

In-Depth [retrospective cohort]: This study used the Veterans’ Affairs database from 2001 to 2008 to select 2948 adult patients initiated on insulin following metformin and 39990 patients who were instead initiated on sulfonylureas. After matching for known/measured confounders, 2436 patients from the insulin group were compared to 12180 patients from the sulfonylurea group for the grouped primary outcome of acute myocardial infarction (MI), stroke and all-cause mortality and secondary outcomes including cardiovascular events (MI and stroke), and all-cause mortality. Follow-up period was 1 year for mortality events and 3 years for all other outcomes.

Insulin-metformin co-therapy increased the risk of the grouped primary outcome (acute MI, stroke, and all-cause mortality) relative to co-therapy with sulfonylureas (aHR 1.30; 95% CI, 1.07-1.58; p=0.009). Risk of all-cause deaths was also elevated in the insulin group relative to the sulfonylurea group (aHR 1.44; 95% CI, 1.15-1.79; p=0.001). There was no difference in rates of cardiovascular events (acute MI and stroke).

More from this author: Acamprosate, naltrexone may be effective for alcoholic disorders, Paliperidone and haloperidol demonstrate comparable results in schizophrenia [ACLAIMS trial], Endoscopic sphincterotomy ineffective in reducing post-cholecystectomy abdominal pain [EPISOD trial],  

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.  

Tags: diabetesinsulinmetformintype 2 diabetes
Previous Post

Bariatric weight loss surgery linked with remission in diabetics

Next Post

Diffusion-weighted MRI sensitive for metastasis in pelvic lymph nodes

RelatedReports

Endocrinology

Sodium-glucose co-transporter-2 inhibitors may decrease risk of in-stent thrombosis

March 24, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Endometriosis Awareness Month, OnlineMedEd Charges, Canadian Grocery Store Controversy, BetterHelp’s Privacy Concerns

March 21, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Erythritol and Heart Problems, Maternal Health Trends, the Next Big Thing in Diabetes, and Declining Levels of Sea Ice

March 7, 2023
The Scan by 2 Minute Medicine®:  Ultra-Trail du Mont-Blanc, Taylor Swift, NBA rookie Chet Holmgren and Magic Mushrooms!
The Scan by 2 Minute Medicine®

The Scan by 2 Minute Medicine®: Black History Month, Mr.Beast, Damar Hamlin and on-field CPR, Ozempic Shortage

March 14, 2023
Next Post
MRI helps predict risk of local recurrence in upper rectal cancers

Diffusion-weighted MRI sensitive for metastasis in pelvic lymph nodes

Weight loss may decrease urinary incontinence in male diabetics [Look AHEAD Study]

Hydrolyzed formula in susceptible infants does not reduce Diabetes-linked autoantibodies

Levodopa for Parkinson’s disease more effective than newer generation therapies

Levodopa for Parkinson’s disease more effective than newer generation therapies

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring
  • Hyperfractionated radiotherapy reduces complication rates compared to standard fractionation for locally advanced nasopharyngeal carcinoma
  • Lebrikizumab effective in treating moderate-to-severe atopic dermatitis
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options